Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2017

01-06-2017 | Images

Enoxaparin Induced Skin Lesions in Pregnancy: A Rare But Clinically Recognizable Association

Authors: Sumeet Prakash Mirgh, Abhay A. Bhave

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2017

Login to get access

Abstract

We report the case of a 29 year old pregnant female who experienced itching with erythematous plaques on prophylactic enoxaparin for recurrent fetal losses. These lesions generalized on rechallenge but erythema and itching gradually resolved after 4 weeks of discontinuation. Cutaneous adverse events with heparin have been reported (Villanueva et al. in Actas Dermosifiliogr 103:816–819, 2012; Neloska et al. in Acta Dermatovenerol Croat 23:223–224, 2015; Maldonado et al. in Clin Exp Dermatol 37:707–711, 2012; Schindewolf et al. in Lancet 380:1867–1879, 2012; Tassava and Warkentin in Am J Hematol 90:747–750, 2015), some specifically with enoxaparin (Villanueva et al. 2012; Neloska et al. 2015).
Literature
1.
2.
go back to reference Neloska L, Damevska K, Pavleska L (2015) Enoxaparin-induced skin necrosis. Acta Dermatovenerol Croat 23:223–224PubMed Neloska L, Damevska K, Pavleska L (2015) Enoxaparin-induced skin necrosis. Acta Dermatovenerol Croat 23:223–224PubMed
4.
go back to reference Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH (2012) Heparin induced skin lesions. Lancet 380:1867–1879CrossRefPubMed Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH (2012) Heparin induced skin lesions. Lancet 380:1867–1879CrossRefPubMed
Metadata
Title
Enoxaparin Induced Skin Lesions in Pregnancy: A Rare But Clinically Recognizable Association
Authors
Sumeet Prakash Mirgh
Abhay A. Bhave
Publication date
01-06-2017
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2017
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0719-2

Other articles of this Issue 2/2017

Indian Journal of Hematology and Blood Transfusion 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine